Centessa Pharmaceuticals plc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Centessa Pharmaceuticals plc. | CNTA - NASDAQ |
$18.00-$20.00 | $20.00 | $20.25 | 16.5 million ADSs | 5/28/2021 |
| Morgan Stanley, Goldman Sachs, Jefferies, Evercore ISI | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-04-21 Terms Added 2021-05-24 | ||||||
Centessa Pharmaceuticals plc. Quote & Chart - Click for current quote - CNTA
IPO Boutique aggregates information on public companies and private companies, such as "CNTA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Centessa Pharmaceuticals plc. (adapted from Centessa Pharmaceuticals plc. prospectus):
They are reimagining the traditional pharmaceutical research and development model to build, from the bottom-up, an R&D engine predicated on asset centricity to discover, develop and ultimately deliver impactful medicines to patients.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are reimagining the traditional pharmaceutical research and development model to build, from the bottom-up, an R&D engine predicated on asset centricity to discover, develop and ultimately deliver impactful medicines to patients.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "CNTA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.